EU/3/19/2149

About

On 1 April 2019, orphan designation (EU/3/19/2149) was granted by the European Commission to Brainvectis, France, for adeno-associated viral vector serotype rh10 containing the human cholesterol 24-hydroxylase gene for the treatment of Huntington's disease.

Key facts

Active substance
Adeno-associated viral vector serotype rh10 containing the human cholesterol 24-hydroxylase gene
Disease / condition
Treatment of Huntington’s disease
Date of first decision
01/04/2019
Outcome
Positive
EU designation number
EU/3/19/2149

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Brainvectis
24 Rue Du Faubourg Saint Jacques
75014 Paris
France
Tel.: +33 (0)1 57 27 46 99
E-mail: contact@brainvectis.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating